Lead: Professor David Adams
Team: Early Drug Development
Funded by NIHR Biomedical Research Unit (BRU) Programme.
This group’s remit is to develop phase I and II academic clinical trials in all liver disease including biological therapies (stem cell, vaccines), transplantation, liver cirrhosis, Primary Billiary Cirrhosis, liver cancer and other diseases which affect the liver (Autoimmune, Hepatitis B & C etc.).